Novartis Recalls Single Lot of Diovan Valsartan Over Dissolution Issues; Class II FDA Action Highlights Ongoing Drug Quality Concerns

The U.S. Food and Drug Administration has classified a voluntary recall by Novartis Pharmaceuticals Corporation of one specific lot of its brand-name blood pressure and heart failure medication Diovan (valsartan) as Class II. The affected product is 160-milligram tablets in 90-count bottles, lot number AV5913C, with an expiration date of June 2027. Manufactured by Patheon Manufacturing Services LLC in North Carolina and distributed nationwide by Novartis, the recall stems from failed dissolution specifications, which could reduce the drug's effectiveness as it may not dissolve properly in the body.

Initiated on August 4, 2026, this recall affects a commonly prescribed angiotensin II receptor blocker used to treat hypertension, heart failure, and post-heart attack conditions, impacting an estimated 10.9 million U.S. patients annually. While Class II indicates a low probability of serious adverse effects—potentially temporary or reversible—the issue underscores broader challenges in pharmaceutical manufacturing quality control.

This incident follows a history of valsartan recalls, most notably the 2018 global actions linked to NDMA contamination from suppliers in China and India, which prompted widespread scrutiny of the drug supply chain. More recent recalls include those involving other heart medications like dabigatran etexilate and combinations of amlodipine and olmesartan, often due to impurity or degradation issues. Experts note that dissolution failures, though distinct from contamination risks, can still lead to suboptimal therapeutic outcomes for patients reliant on consistent dosing.

Patients are advised to check their medication bottles and consult healthcare providers or pharmacists rather than abruptly stopping treatment. The FDA maintains a searchable recall database to track such events, emphasizing proactive monitoring of drug safety.